Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Bacterial blood microbiome of rodents captured from a human/livestock/wildlife interface in rural South Africa

PROVIDER: PRJNA546130 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR9194180_subreads.fastq.gz	Fastqsanger.gz
	SRR9194190_subreads.fastq.gz	Fastqsanger.gz
	SRR9194200_subreads.fastq.gz	Fastqsanger.gz
	SRR9194181_subreads.fastq.gz	Fastqsanger.gz
	SRR9194191_subreads.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 25

Similar Datasets

Project description:Wildlife-livestock interface metagenome

| PRJNA832550 | ENA

Project description:Wildlife-livestock interface whole genome sequencing

| PRJNA841939 | ENA

Project description:The characterization of the bacterial blood microbiome of dogs, cattle and acute febrile illness patients in a human/livestock/wildlife interface in Mnisi Community South Africa

| PRJNA602191 | ENA

Project description:Barcode of Wildlife South Africa

| PRJNA301744 | ENA

Project description:Rural livestock farming

| PRJNA953332 | ENA

Project description:South African wildlife, human and livestock Brucella spp. genomes

| PRJNA1097985 | ENA

Mukandavire2020 - SEIR model of early COVID-19 transmission in South Africa

Project description:The emergence and fast global spread of COVID-19 has presented one of the greatest public health challenges in modern times with no proven cure or vaccine. Africa is still early in this epidemic, therefore the extent of disease severity is not yet clear. We used a mathematical model to fit to the observed cases of COVID-19 in South Africa to estimate the basic reproductive number and critical vaccination coverage to control the disease for different hypothetical vaccine efficacy scenarios. We also estimated the percentage reduction in effective contacts due to the social distancing measures implemented. Early model estimates show that COVID-19 outbreak in South Africa had a basic reproductive number of 2.95 (95% credible interval [CrI] 2.83–3.33). A vaccine with 70% efficacy had the capacity to contain COVID-19 outbreak but at very higher vaccination coverage 94.44% (95% Crl 92.44–99.92%) with a vaccine of 100% efficacy requiring 66.10% (95% Crl 64.72–69.95%) coverage. Social distancing measures put in place have so far reduced the number of social contacts by 80.31% (95% Crl 79.76–80.85%). These findings suggest that a highly efficacious vaccine would have been required to contain COVID-19 in South Africa. Therefore, the current social distancing measures to reduce contacts will remain key in controlling the infection in the absence of vaccines and other therapeutics.

2024-09-02 | BIOMD0000000978 | BioModels

Mycobacterium bovis WGS from South Africa

Project description:Mycobacterium bovis WGS from South African wildlife species and neighboring livestock

| PRJEB63548 | ENA

Project description:Evidence of Mycobacterium bovis DNA in Shared Water Sources at Livestock-Wildlife-Human Interfaces in KwaZulu-Natal, South Africa

| PRJNA1185125 | ENA

Transcriptome Analysis of Human Peripheral Blood Mononuclear Cells Exposed to Lassa Virus and to the Reassortant ML29, a Vaccine Candidate

Project description:The virulent Lassa fever virus (LASV) and the non-pathogenic Mopeia virus (MOPV) infect rodents and incidentally people in West Africa. The mechanism of LASV damage in human beings is unclear. A live-attenuated reassortant of MOPV and LASV protects rodents and primates from Lassa fever disease. Peripheral blood mononuclear cells from healthy human subjects were expose to either LASV or ML29 in order to identify early cellular responses that could be attributed to the difference in virulence between both viruses. Differential expression of interferon-related genes as well as coagulation-related genes could lead to an explanation for Lassa fever pathogenesis and lead to protective treatments for Lassa fever disease.

2013-11-05 | GSE41300 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data